36 studies found for:    "Cutaneous mastocytosis"
Show Display Options
Rank Status Study
1 Completed Efficacy and Safety of TF002 in Cutaneous Mastocytosis
Condition: Cutaneous Mastocytosis
Intervention: Drug: TF 002
2 Unknown  A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis With Handicap
Conditions: Smouldering Systemic Mastocytosis;   Indolent Systemic Mastocytosis;   Cutaneous Mastocytosis With Handicap;   Mastocytosis
Interventions: Drug: masitinib (AB1010);   Drug: placebo
3 Completed Natural History of Urticaria Pigmentosa in Children
Condition: Urticaria Pigmentosa
Intervention:
4 Completed Cause and Natural Course of Pediatric-Onset Mastocytosis
Condition: Mastocytosis
Intervention:
5 Recruiting Study of Factors Regulating Mast Cell Proliferation
Condition: Mastocytosis
Intervention:
6 Completed Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis
Condition: Mastocytosis
Intervention: Drug: masitinib (AB1010)
7 Unknown  Imatinib in KIT-negative Systemic Mastocytosis
Condition: Systemic Mastocytosis
Intervention: Drug: Imatinib Mesylate
8 Unknown  Molecular Mechanisms and Diagnosis of Mastocytosis
Condition: Mastocytosis
Intervention:
9 Unknown  Phase II PKC412 in Aggressive Systemic Mastocytosis and Mast Cell Leukemia
Conditions: Mastocytosis, Systemic;   Leukemia, Mast-Cell
Intervention: Drug: PKC 412
10 Completed Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V Mutation
Condition: Patients With Mastocytosis With Handicap and Bearing Mutations Asp-816-Val (D816V)
Intervention: Drug: masitinib
11 Active, not recruiting Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
Conditions: Acute Myeloid Leukemia;   Myelodysplastic Syndromes;   Agnogenic Myeloid Metaplasia;   Myelofibrosis;   Hypereosinophilic Syndrome;   Polycythemia Vera;   Mastocytosis;   Leukemia, Myelomonocytic, Chronic
Intervention: Drug: Dasatinib (BMS-354825)
12 Completed
Has Results
Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis
Condition: Systemic Mastocytosis
Intervention: Drug: RAD001 (Everolimus)
13 Completed Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)
Conditions: Leukemia;   Systemic Mastocytosis
Intervention: Drug: Ontak (Denileukin Diftitox)
14 Terminated Cromoglicate in Mastocytosis
Condition: Mastocytosis
Interventions: Drug: Cromoglicate;   Drug: Placebo
15 Recruiting Use of Tamoxifen in Systemic Mastocytosis
Condition: Systemic Mastocytosis
Intervention:
16 Recruiting Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia
Conditions: Aggressive Systemic Mastocytosis;   Mast Cell Leukemia;   Systemic Mastocytosis
Interventions: Drug: brentuximab vedotin;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment;   Other: questionnaire administration
17 Not yet recruiting SL-401 in Advanced, High Risk Myeloproliferative Neoplasms (Systemic Mastocytosis, Advanced Symptomatic Hypereosinoophic Disorder, Myelofibrosis, Chronic Myelomonocytic Leukemia)
Conditions: Myelofibrosis;   Chronic Myelomonocytic Leukemia;   Advanced Systemic Mastocytosis;   Advanced Symptomatic Primary Eosinophilic Disorder
Intervention: Drug: SL-401
18 Recruiting The Effect of Xolair ® (Omalizumab) in Mastocytosis Patients
Condition: Mastocytosis
Intervention: Drug: injections
19 Recruiting Midostaurin in Indolent Systemic Mastocytosis
Condition: Indolent Systemic Mastocytosis
Intervention: Drug: Midostaurin,
20 Completed Study on Mastocytosis for Rupatadine Treatment
Condition: Mastocytosis
Intervention: Drug: Rupatadin

   Previous Page Studies Shown (1-20) Next Page (21-36) Show next page of results    Last Page
Indicates status has not been verified in more than two years